News Updates
January 11, 2023
Intellia Therapeutics Awarded Innovation Passport in the United Kingdom for NTLA-2002, an Investigational Genome Editing Treatment for Hereditary Angioedema
Learn More
January 5, 2023
Intellia Therapeutics Highlights Strategic Priorities and Anticipated 2023 Key Milestones
Learn More
Powered by Juicer